Mutations in the LRRK2 gene, a protein that acts as a kinase, is a common cause of Parkinson’s disease. Researchers have discovered a broad spectrum of kinase inhibitors against LRRK2. For example, indolinones are the most effective at reducing LRRK2's kinase activity.
The parkin and PINK1 genes clear damaged mitochondria from the brain. These genes are not functioning optimally in patients with Parkinson’s disease. Moreover, genes for mitochondrial function are less active in people with Parkinson’s disease. Researchers are studying how PGC-1alpha, a gene that regulates energy metabolism and mitochondrial biogenesis( the production of new mitochondrion)
Lee, B.D. et al. "Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease." Nature Medicine, Vol. 16(9), pp. 998-1000
Zheng B et al. “PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease.” Science Translational Medicine, October 6, 2010, Vol. 2 (52), pp. 1-14
No comments:
Post a Comment